Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this clinical research study is to find the highest tolerable dose of JV-394 (a type of autologous CAR-T cell therapy) that can be given to patients who have T/NK cell lymphoma that is relapsed or refractory. The safety and possible side effects of JV-394 will also be studied.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony nowotwór komórek T/NK badaniem patologicznym
- •Choroba powróciła lub nie reaguje na leczenie standardowe (co najmniej jedno poprzednie leczenie)
- •Co najmniej 50% komórek nowotworu wykazuje markery CD94
- •Przerwa co najmniej 2 tygodnie od ostatniego leczenia przeciwnowotworowego
- •Ogólny stan zdrowia pozwalający na udział w badaniu (ocena 0-1)
- •Co najmniej jeden mierzalny guz
- •Prawidłowe wyniki krwi i funkcja nerek
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 15, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
The University of Texas M. D. Anderson Cancer Center
Houston, United States
Trial contact
Sattva S Neelapu, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/16/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.